Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
KPTI Karyopharm Therapeutics
3.520+0.150+4.45%
Close
02/07 16:00 ET
High
3.540
Open
3.340
Turnover
7.37M
Low
3.325
Pre Close
3.370
Volume
2.15M
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
FY2022 EPS Estimates for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Lowered by Jefferies Financial Group
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) – Research analysts at Jefferies Financial Group lowered their FY2022 earnings per share (EPS) estimates for Karyopharm Therapeutics in a res
Karyopharm Therapeutics Inc. Forecasted to Earn Q1 2023 Earnings of ($0.30) Per Share (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q1 2023 EPS estimates for Karyopharm Therapeutics in a research note i
KPTI, BIRD and KTCC Are Among After Hour Movers
Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $5.00
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its price target decreased by analysts at Morgan Stanley from $7.00 to $5.00 in a note issued to investors on Friday, Benzinga reports. The fir
Karyopharm Therapeutics Price Target Cut to $5.00/Share From $7.00 by Morgan Stanley
Karyopharm Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Karyopharm Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Karyopharm Therapeutics, Lowers Price Target to $5
Morgan Stanley analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Equal-Weight and lowers the price target from $7 to $5.
KPTI, VRNA and SGH Are Among After Hour Movers
Analyst Ratings for Karyopharm Therapeutics
Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings12200Last 30D01000
Karyopharm Gains as Piper Issues Bullish Remarks Citing Cancer Drug
Company Overview
More
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
CEO： Mr. Richard Paulson
Market： NASDAQ
Listing Date： 11/06/2013
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet